felin
infecti
periton
coin
wolf
griesem
earli
recogn
immunopatholog
compon
pedersen
boyl
jacobsegeel
et
al
antibodydepend
enhanc
ade
shown
play
part
pathogenesi
diseas
pedersen
weiss
scott
olsen
et
al
first
vaccin
fip
intranas
modifi
live
viru
mlv
vaccin
licens
gerber
et
al
gerber
current
statu
fip
vari
type
cat
popul
fear
diseas
today
breed
catteri
less
common
less
concern
gener
pet
popul
wolf
kass
dent
effect
treatment
fip
classic
diseas
occur
mortal
nearli
avail
commerci
vaccin
less
effect
avail
laboratori
test
detect
felin
coronaviru
antibodi
therefor
specif
fip
recent
test
detect
fip
antigen
viru
identifi
viru
carrier
cat
reliabl
new
antigen
detect
test
still
evalu
catteri
enzoot
fip
difficult
manag
great
variabl
incub
period
fip
week
month
even
year
present
seriou
challeng
prevent
control
comprehens
review
fip
viru
publish
olsen
review
cover
molecular
biolog
viru
immunopathogenesi
infect
clinic
aspect
diseas
discuss
vaccin
fip
two
review
fipv
publish
de
groot
horzinek
pedersen
seri
manuscript
publish
felin
practic
proceed
intern
workshop
fipv
fecv
vol
caus
agent
fip
felin
infecti
periton
viru
fipv
pleomorph
envelop
viru
classifi
coronaviru
singlestrand
positivesens
rna
genom
viru
contain
three
major
structur
protein
n
nuclear
protein
core
protein
matrix
glycoprotein
formerli
call
el
spike
glycoprotein
formerli
call
de
groot
horzinek
olsen
spaan
et
al
least
two
cell
receptor
fipv
infect
cell
de
groot
horzinek
holm
compton
olsen
et
al
olsen
et
al
olsen
one
viru
receptor
cell
membran
specif
epitop
protein
second
fc
receptor
macrophag
fc
portion
igg
antibodi
replic
fipv
occur
endoplasm
membran
infect
cell
holm
olsen
viru
bud
vacuol
within
cell
cytoplasm
henc
viru
remain
cellassoci
initi
viru
releas
infect
cell
cell
destroy
cytolysi
replic
viru
rapid
replic
cycl
complet
less
hour
fipv
surviv
environ
much
longer
origin
thought
infecti
fipv
recov
contamin
dri
surfac
week
room
temperatur
amount
infecti
viru
present
gradual
decreas
time
scott
highli
labil
viru
usual
report
fipv
one
four
virus
make
antigen
cluster
virus
similar
genom
second
viru
felin
enter
coronaviru
fecv
gener
produc
mild
enter
fip
howev
indic
fecv
produc
fiplik
diseas
posit
antibodi
titer
fipv
result
fecv
infect
prefer
refer
fipv
fecv
felin
coronaviru
fcov
third
viru
group
canin
coronaviru
ccv
infect
cat
usual
subclin
infect
ccv
antibodyposit
cat
experi
ade
fipv
infect
mcardl
et
al
one
uk
isol
ccv
produc
clinic
fip
cat
posit
antibodi
titer
fipv
produc
experiment
ccv
infect
cat
last
viru
group
transmiss
gastroenter
viru
tgev
swine
tgev
infect
cat
usual
subclin
infect
posit
antibodi
titer
fipv
wood
pedersen
felin
coronavirus
belong
singl
serotyp
two
subtyp
viru
differenti
monoclon
antibodi
mab
teramoto
hohdatsu
et
al
olsen
pathogenesi
fcov
infect
complex
uniqu
incub
period
week
month
even
year
gener
week
month
local
infect
primari
infect
occur
pharyng
lung
epithelium
possibl
intestin
epithelium
de
groot
horzinek
olsen
minim
clinic
diseas
primari
infect
often
transient
fever
one
day
antibodi
fipv
first
appear
serum
day
day
infect
infect
macrophag
occur
fc
receptor
macrophag
enabl
uptak
virusantibodi
complex
infect
macrophag
transport
viru
throughout
bodi
secondari
infect
occur
mani
tissu
macrophag
attach
migrat
wall
vein
perivascular
reaction
occur
lead
develop
pyogranuloma
basic
lesion
fip
within
tissu
two
form
fip
recogn
montali
strandberg
earli
report
describ
fip
primarili
wet
exud
fip
current
dri
granulomat
fip
common
wet
form
diseas
wet
dri
form
fip
mere
variat
diseas
process
wet
fip
exud
reaction
vessel
wall
exud
fluid
accumul
periton
andor
thorac
caviti
immunolog
fcov
infect
complic
fulli
understood
undoubtedli
three
major
compon
host
immun
respons
come
play
fulli
immun
cat
howev
mani
cat
develop
aspect
immun
respons
without
develop
protect
case
host
respons
make
cat
suscept
exposur
fipv
rather
provid
protect
humor
immun
result
serum
viru
neutral
vn
antibodi
first
appear
day
infect
gradual
increas
vn
titer
week
infect
hypergammaglobulinemia
occur
cat
develop
clinic
fip
vn
antibodi
epitop
spike
protein
usual
enhanc
antibodi
right
concentr
viru
antibodi
exist
subclass
igg
produc
may
import
determin
true
immun
occur
cellmedi
immun
cmi
believ
play
essenti
role
effect
immun
respons
fcov
pedersen
pedersen
detail
cmi
respons
determin
local
immun
appear
play
signific
role
prevent
infect
previous
infect
vaccin
cat
via
antifcov
iga
mucos
surfac
gerber
gerber
et
al
immun
enhanc
antibodydepend
enhanc
ade
clearli
shown
occur
experiment
laboratori
infect
cat
previous
infect
natur
experiment
infect
cat
previous
vaccin
primucel
fip
vaccin
experiment
mlv
vaccin
experiment
inactiv
vaccin
experiment
recombin
vaccin
contain
gene
mcardl
et
al
mcardl
et
al
ngichab
scott
et
al
scott
et
al
weiss
scott
antibodi
protein
produc
host
result
enhanc
infect
macrophag
via
fc
receptor
infect
macrophag
transport
viru
throughout
bodi
enhanc
infect
decreas
incub
timema
short
day
exposur
virul
fipv
rel
amount
viru
antibodi
import
order
ade
occur
higher
concentr
antibodi
neutral
viru
concentr
antibodi
decreas
concentr
occur
enhanc
infect
result
relat
coronavirus
caus
enhanc
fcov
infect
cat
includ
ccv
infect
macrophag
appear
key
factor
abil
fcov
becom
system
infect
pedersen
stoddart
scott
infect
macrophag
travel
bloodstream
variou
part
bodi
attach
wall
vein
local
infect
inflamm
result
characterist
perivascular
lesion
identifi
pyogranuloma
singl
commerci
vaccin
primucel
fip
pfizer
avail
aid
protect
cat
fip
fcov
infect
christianson
et
al
gerber
gerber
et
al
mlv
temperaturesensit
ts
mutant
produc
attenu
origin
virul
isol
serial
passag
cell
cultur
low
temperatur
isol
type
viru
primucel
fip
licens
intranas
administr
two
dose
given
week
apart
cat
least
week
age
annual
revaccin
recommend
manufactur
vaccin
stimul
local
iga
vn
antibodi
titer
serum
gerber
gerber
et
al
evalu
risk
benefit
associ
use
vaccin
complic
issu
first
sever
usual
fatal
natur
fip
mandat
need
safe
effect
vaccin
especi
sinc
effect
treatment
diseas
highli
effect
vaccin
fip
avail
would
use
routin
felin
practic
risk
vaccin
primucel
fip
appear
minim
situat
vaccin
use
past
year
increas
incid
fip
report
field
safeti
test
control
field
studi
document
increas
fip
relat
diseas
cat
vaccin
vaccin
fehr
et
al
hoskin
et
al
reev
scott
et
al
experiment
studi
sever
laboratori
howev
ade
infect
document
cat
vaccin
vaccin
varieti
experiment
fip
vaccin
mcardl
et
al
ngichab
scott
et
al
vennema
et
al
situat
enhanc
state
result
shorter
incub
period
exposur
virul
viru
shorter
cours
diseas
sever
clinic
sign
greater
mortal
compar
unvaccin
control
cat
major
factor
determin
whether
enhanc
diseas
occur
rel
concentr
virul
viru
antifcov
antibodi
olsen
olsen
et
al
olsen
et
al
scott
et
al
investig
state
ade
infect
occur
natur
field
condit
occur
laboratori
condit
fehr
et
al
reev
although
ade
appear
major
problem
field
condit
appar
due
rel
small
amount
viru
shed
infect
carrier
cat
virtual
imposs
determin
individu
case
fip
result
ade
infect
nonenhanc
infect
incub
period
differenti
differ
ade
infect
result
sever
clinic
fip
within
day
exposur
viru
scott
et
al
weiss
scott
nonenhanc
infect
result
sever
diseas
day
exposur
sinc
time
exposur
viru
almost
alway
imposs
determin
field
infect
likewis
virtual
imposs
determin
certainti
whether
particular
infect
enhanc
one
studi
safeti
efficaci
vaccin
two
highrisk
cat
popul
switzerland
fehr
et
al
author
state
vaccin
result
enhanc
diseas
yet
evalu
report
result
indic
three
cat
develop
fip
within
first
month
vaccin
none
placebo
vaccin
cat
develop
fip
within
time
case
enhanc
diseas
imposs
ascertain
also
imposs
rule
enhanc
diseas
base
data
benefit
vaccin
unfortun
rather
low
fip
endem
catteri
two
control
studi
fail
show
decreas
incid
fip
vaccin
cat
compar
placebo
vaccin
control
origin
field
studi
manufactur
vaccin
fanton
endem
catteri
evalu
control
studi
cat
vaccin
twice
primucel
fip
cat
vaccin
placebo
vaccin
observ
period
month
three
case
fip
occur
vaccin
group
compar
four
case
control
group
differ
statist
signific
doubleblind
placebo
control
field
studi
switzerland
involv
purebr
cat
catteri
fehr
et
al
investig
unabl
show
differ
primucel
fip
vaccin
cat
placebo
vaccin
control
within
fip
endem
catteri
vaccin
use
recommend
manufactur
two
dose
vaccin
given
week
apart
start
week
age
seven
fip
death
vaccin
group
five
fip
death
placebo
group
studi
period
endem
catteri
mani
kitten
infect
carrier
queen
week
age
long
vaccin
use
licens
week
age
stoddart
et
al
cat
infect
fcov
vaccin
benefici
effect
control
studi
efficaci
vaccin
kitten
younger
week
age
publish
catteri
owner
appar
use
vaccin
label
kitten
young
week
age
highrisk
pet
cat
popul
limit
efficaci
vaccin
switzerland
studi
mention
earlier
fehr
et
al
domest
purebr
household
pet
cat
studi
doubleblind
placebo
control
field
studi
month
vaccin
fip
confirm
death
vaccin
group
compar
death
control
group
author
state
death
loss
placebo
vaccin
group
equal
day
follow
immun
significantli
placeboimmun
anim
die
fip
period
author
review
data
studi
fehr
et
al
two
death
vaccin
group
n
compar
control
group
n
day
equal
number
death
fip
n
group
day
vaccin
period
four
death
control
group
death
vaccin
group
disturb
find
two
death
vaccin
group
occur
within
first
day
vaccin
none
death
control
group
occur
within
time
period
cat
mere
incub
diseas
time
vaccin
would
die
anyway
earli
death
vaccin
result
enhanc
diseas
vaccin
cat
alreadi
antibodi
posit
imposs
review
ascertain
exact
situat
two
cat
case
primucel
fip
reduc
incid
fip
within
highrisk
pet
popul
cat
month
vaccin
cat
least
year
age
topic
intranas
vaccin
primucel
fip
stimul
vn
antibodi
within
sera
vaccin
cat
fehr
et
al
hoskin
et
al
scott
et
al
scott
et
al
vn
antibodi
direct
epitop
protein
viru
also
enhanc
antibodi
test
vitro
infect
periton
macrophag
scott
et
al
stoddart
scott
studi
cat
vaccin
primucel
fip
enhanc
antibodi
within
sera
vaccin
none
unvaccin
control
enhanc
antibodi
enhanc
infect
occur
efficaci
primucel
fip
depend
dose
fipv
vaccin
cat
expos
mcardl
et
al
scott
et
al
b
experiment
condit
vaccin
cat
expos
low
dose
virul
challeng
viru
cat
infecti
dose
vaccin
provid
protect
cat
vaccin
cat
expos
cat
infecti
dose
fipv
tcidso
vaccin
provid
protect
higher
challeng
dose
mani
vaccin
cat
suscept
infect
unvaccin
control
result
enhanc
acut
diseas
efficaci
vaccin
demonstr
fcov
antibodyneg
cat
vaccin
accord
manufactur
recommend
prior
natur
exposur
fcovinfect
cat
reev
report
signific
reduct
clinic
fip
fcov
antibodyneg
cat
vaccin
twice
least
week
age
introduc
larg
cat
shelter
fip
endem
vaccin
mortal
fip
period
vaccin
compar
fip
mortal
placebovaccin
cat
calcul
efficaci
vaccin
base
prevent
fraction
hoskin
et
al
b
evalu
efficaci
primucel
fip
kitten
vaccin
week
age
two
studi
one
studi
number
kitten
histopatholog
indic
fip
lowdos
challeng
reduc
vaccin
cat
compar
unvaccin
control
efficaci
base
prevent
fraction
studi
vaccin
kitten
expos
less
intestin
clinic
diseas
less
viru
intestin
less
histopatholog
damag
small
intestin
compar
unvaccin
control
amount
viru
cat
expos
normal
field
condit
unknown
howev
base
studi
report
date
natur
experiment
condit
one
conclud
amount
viru
exposur
must
low
exposur
dose
viru
high
enhanc
diseas
would
frequent
encount
enhanc
diseas
occur
natur
condit
least
uncommon
occurr
exposur
dose
viru
must
low
level
consist
known
amount
viru
shed
experiment
infect
cat
publish
inform
durat
immun
produc
primucel
fip
veterinari
biolog
manufactur
vaccin
arbitrarili
recommend
annual
revaccin
summari
primucel
fip
vaccin
efficaci
prevent
clinic
fip
fcov
antibodyneg
kitten
least
week
age
vaccin
twice
intranas
week
apart
vaccin
shown
reduc
incid
clinic
fip
use
endem
catteri
vaccin
routin
given
kitten
least
week
age
use
vaccin
appear
limit
highrisk
popul
breed
catteri
multicat
facil
fcov
antibodyneg
cat
vaccin
american
associ
felin
practition
felin
vaccin
guidelin
elston
et
al
make
follow
recommend
concern
fip
vaccin
panel
consid
noncor
vaccin
low
preval
diseas
confin
popul
cat
result
vaccin
recommend
cat
risk
exposur
caus
organ
howev
panel
split
constitut
risk
exposur
fipinduc
coronavirus
minor
panel
member
recommend
vaccin
kitten
cat
lifestyl
result
substanti
risk
exposur
coronavirus
panel
member
recommend
vaccin
limit
cat
specif
risk
situat
household
fip
diagnos
cat
vaccin
deem
appropri
receiv
foundat
seri
vaccin
kitten
accord
recogn
protocol
annual
booster
vaccin
recommend
vaccin
manufactur
howev
knowledg
durat
immun
studi
perform
